Elan Corp is primarily active in the pharmaceutical and biotechnology industries.

The main competitors of Elan Corp in the market include Biogen Inc., Novartis AG, Takeda Pharmaceutical Company Limited, and Amgen Inc.

Elan Corp is a renowned pharmaceutical company with a rich history and background. Established in 1969, it has grown into a global player in the biotechnology industry. Elan Corp focuses on developing innovative therapies for various medical conditions, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Over the years, the company has gained recognition for its cutting-edge research and development initiatives. With a strong commitment to improving patient outcomes, Elan Corp has built a reputation for delivering high-quality products that address critical unmet medical needs. Today, it continues to prioritize advancements in healthcare through its dedicated team of scientists, researchers, and healthcare professionals.

Elan Corp, a leading pharmaceutical company, has achieved numerous significant milestones. One of the notable achievements includes the development and launch of Tysabri, a breakthrough treatment for multiple sclerosis. Another milestone is the successful collaboration with Biogen on Tysabri, which showcased the company's strong expertise in partnerships. Elan Corp has also embarked on several successful acquisitions, such as its merger with Perrigo in 2013, expanding its portfolio and global reach. Moreover, the company's dedication to innovation is evident through continuous research and development efforts, leading to the advancement of novel therapies in various therapeutic areas.

Elan Corp is primarily present in multiple countries and regions worldwide. With a global presence, the company operates in various key markets, including the United States, Ireland, and other parts of Europe. Additionally, Elan Corp has established a prominent presence in emerging markets such as Asia and Latin America, further expanding its reach and potential for growth. By strategically expanding their operations across different geographies, Elan Corp aims to tap into diverse markets and leverage regional opportunities to drive success and enhance shareholder value.

Elan Corp represents values of innovation, collaboration, and patient-centered focus. The company's corporate philosophy emphasizes the development of groundbreaking therapies and solutions to improve the lives of patients worldwide. With an extensive portfolio of research and development, Elan Corp aims to lead the way in healthcare advancements, ensuring excellence in quality, safety, and efficacy of its products. By leveraging its expertise and strategic partnerships, Elan Corp strives to make a positive impact on the healthcare industry and contribute to the betterment of society.

Analysts currently set an average price target of 1020,00 JPY for the Elan stock (median: 1020,00 JPY), implying +34,0 % versus the latest price. The consensus is based on 6 analyst ratings.

Elan Prezzi Obiettivo Analisti 2026

7 analysts currently rate the Elan stock: 0 recommend buying, 3 holding and 4 selling. For 2026, analysts expect Elan to generate revenue of 60,60 miliardi JPY and earnings per share of 52,60 JPY.

Elan Prezzi Obiettivo Analisti 2026

Converted at the current exchange rate, the Elan share trades at 4,10 EUR (761,00 JPY).

The Elan share (6099.T) is listed on 2 stock exchanges, including: Frankfurt (25E.F).

Elan Corp is an Irish pharmaceutical company that focuses on the development, manufacturing, and marketing of specialized medicines. It serves both the US and European markets with a focus on unmet medical needs and innovative technologies. The article describes Elan's business model, key business areas, and products as well as its market orientation. Elan Corp's business model encompasses the entire value chain from research and development to production and sales of pharmaceutical products. The company focuses on developing and licensing innovative technologies in the medical industry and has a coordinated and differentiated product portfolio. Elan Corp operates three business areas: biopharmaceuticals, product innovations, and Elan Drug Technologies (EDT). The biopharmaceuticals division specializes in developing drugs for neurodegenerative diseases such as Alzheimer's, Parkinson's, and multiple sclerosis, with Tysabri being a well-known product in this area. The product innovations division conducts an intensive research and development program aimed at discovering and launching new products. The EDT division offers a variety of patented and innovative technologies for improving drug delivery and absorption. Elan offers a wide portfolio of medications for the treatment of neurodegenerative diseases, autoimmune diseases, and cancer. The company provides various products and technologies, including proprietary technologies for enhancing drug efficacy and reducing adverse effects, for the therapy of various diseases and medical conditions. Elan Corp specializes in the development of Tysabri, a medication for the treatment of multiple sclerosis. It is a monoclonal antibody drug administered as an infusion that slows disease progression and reduces the frequency of relapses. Elan Corp is an internationally operating company specializing in the US and European markets. It particularly relies on targeted local marketing and sales strategies to expand its customer base and provide comprehensive product information. In summary, Elan Corp focuses on the development and marketing of medications for the treatment of neurodegenerative diseases, cancer, and autoimmune diseases. The company operates a coordinated portfolio and utilizes patented technologies to improve drug efficacy and reduce adverse effects. Elan has particularly focused on the US and Europe and is known in the industry as an innovative, future-oriented provider.

Il attesa fatturato di Elan ammonta a 60,60 miliardi JPY. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.

Il attesa profitto di Elan ammonta a 3,18 miliardi JPY. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.

Il rapporto prezzo/utili (P/E) di Elan è attualmente 14,47. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Elan.

Il rapporto prezzo/fatturato (P/S) di Elan è attualmente 0,76. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Elan.

Il Quality Score AlleAktien per Elan è 8/10.

L'ISIN di Elan è JP3167680002. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.

Il WKN di Elan è A12C13. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.

Il ticker di Elan è 6099.T. Con questo simbolo di borsa vengono negoziate le azioni Elan in borsa.

Negli ultimi 12 mesi, Elan ha pagato un dividendo di 15,00 JPY . Ciò corrisponde a un rendimento da dividendo di circa 1,97 %. Per i prossimi 12 mesi, si prevede che Elan pagherà un dividendo di 28,00 JPY.

Il rendimento da dividendo attuale di Elan è 1,97 %.

Elan paga un dividendo, distribuito nei mesi di , , , .

Elan ha pagato dividendi ogni anno negli ultimi 12 anni.

Per i prossimi 12 mesi, si prevedono dividendi per un importo di 28,00 JPY. Ciò corrisponde a un rendimento da dividendo di 3,68 %.

Elan è assegnato al settore 'Sanità'.

Per ricevere l'ultimo dividendo di Elan del per un importo di 15 JPY, dovevi avere il titolo nel tuo portafoglio prima della data di stacco il .

L'ultimo dividendo è stato distribuito il .

Nell'anno 2025, Elan ha distribuito 13 JPY come dividendi.

I dividendi di Elan sono distribuiti in JPY.